Further, PD‐1/PD‐L1 monoclonal antibodies also contribute to anti‐tumor angiogenesis, complementing each other to exert a synergistic effect.[6] These facts prompt us to combine these two drugs in one nanoplatform to maximize therapeutic efficacy for HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.